Fail Safe Cell Therapy

1-888-613-6862
info@pancella.com

Author Archives: jasonashley

panCELLa’s founder and CSO Dr. Nagy to present at European Society of Gene and Cell Therapy XXV Anniversary Congress

October 17, 2017 – 8 am | Add to Google Calendar Berlin On the morning of October 18th, Dr. Nagy, along with Robin Ali, will be chairing discussions on Disease Modelling. Later in the afternoon, in a session on “Stem cells: Biology, manipulation and reprogramming” sponsored by Bluebird Bio, Dr. Nagy will be giving a presentation on… Continue Reading

Does Brain Tissue Regeneration Depend on Maturity of Stem Cells Used for Transplantation?

New research has shown that the success of transplanting stem cells into the brain to regenerate tissue damaged by stroke may depend on the maturity of the neuronal precursor cells used for transplantation. A study demonstrating the significant impact of human neuronal precursor cell maturity on cell survival after transplantation into stroke-injured rate brains is published in hTissue Engineering, Part A, peer-reviewed journal from Mary Ann Liebert, Inc., publishers… Continue Reading

Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34+ Cells for Correction of Fabry Disease.

Fabry disease is a rare lysosomal storage disorder (LSD). We designed multiple recombinant lentivirus vectors (LVs) and tested their ability to engineer expression of human α-galactosidase A (α-gal A) in transduced Fabry patient CD34+ hematopoietic cells. We further investigated the safety and efficacy of a clinically directed vector, LV/AGA, in both ex vivo cell culture studies and animal models. …. Continue Reading

Concise Review: Wharton’s Jelly: The Rich, but Enigmatic, Source of Mesenchymal Stromal Cells.

The umbilical cord has become an increasingly used source of mesenchymal stromal cells for preclinical and, more recently, clinical studies. Despite the increased activity, several aspects of this cell population have been under-appreciated. Key issues are that consensus on the anatomical structures within the cord is lacking, and potentially different populations are identified as arising from a single source. To help address these points, we propose a histologically based nomenclature for cord structures and provide an analysis of their developmental origins and composition…. Continue Reading

CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Daclizumab, a humanized monoclonal antibody, binds CD25 and blocks formation of the IL-2 receptor on T cells. A study of daclizumab as acute graft-versus- host disease (GVHD) prophylaxis after unrelated bone marrow transplantation was conducted before the importance of CD25+FOXP3+ regulatory T cells (Tregs) was recognized. Tregs can abrogate the onset of GVHD. The relation between Tregs and a graft-versus-malignancy effect is not fully understood….. Continue Reading